Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Celljuvant Study
NCT06015282Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Nov 2023
- Primary completion
- Mar 2024
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 8
01
Overview
A Phase 3 trial of Influenza vaccine surface antigen adjuvanted with MF59 in influenza, sponsored by CSL Seqirus. Started Nov 2023; status: completed.
02
Drugs
Influenza vaccine surface antigen adjuvanted with MF59
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06015282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015282.